Novartis
Tracked across 41 events · 330 articles · First seen Apr 22, 2025 · Last active Aug 20, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: Novartis announced the expansion of its community health programs to address gaps in heart disease and cancer care globally, which could positively impact its public image and long-term market position.
Apr 09, 2026 · 7 articles
Regulatory
Impact: Novartis received International — European Commission approval for its gene therapy Itvisma, expanding its market reach for spinal muscular atrophy treatments and reinforcing its position in gene therapy. This approval is a significant positive for the company.
Jul 02, 2026 · 7 articles
Tech
Impact: As the company presenting the new data, Novartis's immunology portfolio is highlighted, potentially boosting its market position and future revenue prospects. The positive clinical trial results for its key drugs could lead to increased investor confidence.
May 31, 2026 · 6 articles
Business
Impact: Novartis is acquiring Myricx Bio to strengthen its oncology pipeline with next-generation antibody-drug conjugates (ADCs) and novel NMTi payload mechanisms, expanding its options for cancer patients and potentially establishing a new class of ADC payloads.
Jul 05, 2026 · 21 articles
Business
Impact: Novartis transitions to private equity ownership, appoints new CEO and board, and will rebrand; the company gains focus and resources for growth.
Jul 29, 2026 · 6 articles
Regulatory
Impact: Novartis received FDA approval to expand Pluvicto's indication to mHSPC, nearly doubling the eligible patient population and reinforcing its leadership in radioligand therapy. This is expected to drive future revenue growth, though the stock dipped 1.45% on the announcement.
Jul 31, 2026 · 6 articles
Regulatory
On August 13, 2026, London's United Kingdom — High Court of Justiciary ruled in favor of Swiss drugmaker Novartis in a patent dispute over its blockbuster heart drug Sacubitril/valsartan. Judge Richard Meade rejected a challenge…
Impact: Novartis is the patent holder and beneficiary of the court ruling, which protects its blockbuster drug Sacubitril/valsartan from generic competition in the UK, supporting its revenue and market position.
Aug 13, 2026 · 6 articles
Business
Impact: Novartis settled a lawsuit with the estate of Henrietta Lacks over the unauthorized use of her cells, which were used to develop various medical advancements. This settlement resolves a significant legal and ethical challenge for Novartis.
Feb 26, 2026 · 7 articles
Business
Impact: Novartis, an innovative medicines company, is collaborating with the United Arab Emirates — Department of Health – Abu Dhabi to expand its global scientific expertise in genomics research and advanced therapies, potentially leading to new treatment developments and market opportunities.
Jun 26, 2026 · 6 articles
Regulatory
Impact: Novartis is among the pharmaceutical companies that agreed to lower drug prices for United States — Medicaid and cash payers as part of the deals with the Donald Trump administration.
Dec 19, 2025 · 7 articles
Tech
Impact: Novartis, the manufacturer of Onasemnogene abeparvovec, views this approval as a milestone in patient care and a reflection of its commitment to neurology and expanding its focus into neuroimmunology, neurodegenerative disorders, and neuromuscular diseases.
Dec 20, 2025 · 6 articles
Business
Impact: Novartis is a key player in the antibody therapeutics market, benefiting from the projected market growth.
Jul 28, 2026 · 6 articles
International
Impact: Novartis is a key investor, announcing two U.S. projects: a biomedical research center in San Diego and a cancer-drug production facility in Texas.
Jun 07, 2026 · 7 articles
Tech
Impact: Novartis partnered with Dr. Carl H. June, leading to the development and FDA approval of Tisagenlecleucel, the first CAR-T therapy, which significantly boosted the company's position in advanced cancer treatments.
Jun 16, 2026 · 8 articles
Business
Impact: Novartis participated in the symposium, demonstrating its commitment to green chemistry and sustainable manufacturing.
Jul 20, 2026 · 6 articles
Tech
Impact: Novartis is using machine learning and advanced analytics to build intelligent manufacturing systems and integrate AI across production environments, showcasing the industry's move towards Pharma 4.0.
Apr 07, 2026 · 8 articles
Regulatory
Impact: Novartis' Fabhalta and Vanrafia are among the competitors to TRUTAKNA in IgAN.
Jul 07, 2026 · 6 articles
Business
Impact: Novartis reported strong Pluvicto sales growth, indicating a booming radiopharma market that could benefit PentixaFor's launch.
Jul 15, 2026 · 10 articles
International
Impact: Novartis employed Jason Thomas, a pharmaceutical researcher who was found dead after disappearing, adding a pharmaceutical link to the broader pattern of mysterious deaths.
Apr 11, 2026 · 6 articles
Tech
Impact: Novartis was an attendee at the summit, suggesting its engagement with digital health technologies for clinical trials.
Jul 03, 2026 · 8 articles
Business
Impact: Novartis' Leqvio is another competitor in the PCSK9 inhibitor market. Scribe's progress may affect Novartis's competitive position.
Jul 06, 2026 · 25 articles
Regulatory
Impact: Novartis is mentioned as the former parent company of CIBA Vision, from which EyeSense, a spin-off, originated. This provides historical context for FiberSense's expertise but does not indicate a direct impact from this event.
Jun 17, 2026 · 7 articles
Business
Impact: Dhavalkumar Patel>>> spent 10 years at Novartis>>> as Head of Research for NIBR Europe.
Jun 12, 2026 · 6 articles
Domestic
Impact: Novartis>>> shed 0.3%-0.7% in one session but moved up by 1.85% in another, showing mixed performance in the Switzerland>>> market.
May 21, 2026 · 8 articles
Business
Impact: Competitor in acromegaly market.
Jul 06, 2026 · 34 articles
Business
Impact: Novartis is mentioned as a previous employer where Dr. Zack worked in the Biotherapeutics Development Unit.
Jul 27, 2026 · 6 articles
Business
Dassault Systèmes — Medidata Solutions, a Dassault Systèmes brand and leading provider of clinical trial solutions, announced key appointments to its executive leadership team on August 10, 2026. Lisa Moneymaker, who joined the executive committee…
Impact: Novartis is mentioned as a previous employer of Ian Marks, providing context for his experience but not directly affected by the event.
Aug 10, 2026 · 6 articles
Business
National Stock Exchange of India is considering allowing its own shares to trade on its platform under the 'permitted to trade' category after formally listing on rival JSE Limited. This proposal, discussed with global investors…
Impact: Novartis is also among the companies trading on NSE under the permitted-to-trade category, further illustrating the existing framework.
Aug 20, 2026 · 6 articles
Business
Impact: Novartis led AstronauTx's £48 million/$61 million Series A financing in October 2023.
May 12, 2026 · 6 articles
Business
Impact: Novartis is listed as a previous employer of Jenkins; no direct impact from this event.
Jul 15, 2026 · 6 articles
+ 11 more events
View on Dashboard
ERGEN INTELLIGENCE
Track Novartis live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard